>> What does that mean? Was it based on adverse events at the higher doses or did the PK info cause Genaera to feel that the drug's distribution/elimination characteristics enabled a lower dose. The statements' ambiguity causes me to lean towards negative assumptions. <<
You’re absolutely right about the ambiguity –there are always two ways to interpret these kinds of events. In this case, I lean toward the positive interpretation because:
1. Squalamine showed a good safety profile in cancer trials at doses as high as 800mg/day and 4,000mg/week (#msg-3892760)!
2. The 10mg AMD dose was not a bolt from the blue but rather a part of the protocol for the 18-patient PK trial.
-- Where I think GENR may be spinning things is in its contention that adding the 10mg dose to the Visudyne combo trial necessitated a long delay in starting the trial. I don’t buy this; adjusting a phase-2 protocol to add a dose should be a relatively quick and simple process. As stated in my one of my prior posts, I think a shortage of available drug was probably responsible for at least part for he delay in launching the combo trial.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.